



The Off-Patent Medicines Industry: A Strategic Partner for Europe

TUESDAY 9 JUNE 2026

18.30 – 21.30



Welcome cocktail and registration

WEDNESDAY 10 JUNE 2026

13.30 – 14.00



Welcome coffee and registration

14.00 – 14.25



Conference welcome: Theodore Tryfon - CEO, Elpen
Keynote Opening Address: Kyriakos Mitsotakis - Prime Minister of Greece

14.25 – 15.00



Session 1 – The off-patent medicines industry - a strategic partner for Europe

Europe faces a decisive geopolitical momentum which is also reflected in the health and pharmaceutical agenda: reinforce health security, ensure equitable access to medicines, and restore health industrial competitiveness. The off-patent medicines sector is indispensable, as the Greek case demonstrates. It delivers most day-to-day essential treatments for patients, supports tens of thousands of high-quality jobs, and ensures the sustainability of health systems. This session will look into the clear political vision which is needed to ensure a secure, competitive and pro-access pharmaceutical environment—one that recognises the off-patent sector as a strategic partner for Europe's competitiveness.

Moderator: Journalist (tbc)

Panellists

- **Adonis Georgiadis** - Minister for Health of Greece (inv)
- **Steffen Saltofte** - CEO, Zentiva



15.00 – 16.15



Session 2 – The off patent medicines industry - a strategic partner for jobs and growth

The European off-patent medicines industry is a key contributor to affordable healthcare, high-quality jobs, and economic growth across Europe. Companies are actively working to increase their competitiveness in the global ecosystem by investing in digitalisation, manufacturing innovation and skills, but a stronger partnership is needed with European institutions to support these investments. The session will examine the broader global landscape, including how different jurisdictions are using public support, fiscal advantages, and long-term industrial strategies to attract and retain pharmaceutical manufacturing. Panellists will discuss how these measures work in practice and what elements must be put in practice to enable a competitive, innovative, and future-proof industrial base which continues to contribute to jobs and growth.

Moderator: Julie Maréchal-Jamil - Executive Director, Medicines for Europe

Presentation by André Guedel - Director, Head Business Development Tax KPMG Switzerland

Panellists

- **Theodore Tryfon** - CEO, Elpen
- **Sophie N'gout** - Sandoz Site Lead France
- **Representative of Office for Life Sciences**, UK (tbc)
- **Nikos Papandreou** - Member of the European Parliament, Greece (inv)
- **Representative of Greek government** (tbc)

16.15 – 16.45



Networking coffee break

16.45 – 17.45



Session 3 spotlight: The off-patent industry – a strategic partner for more coherent policies

There is a growing understanding that in order to compete at a global level the EU must support the competitiveness of its strategic industries. While proposals such as the Critical Medicines Act or the Biotech Act aim to deliver this, other disproportionate and conflicting policies raise significant barriers to the functioning of the off-patent industry. The Urban Wastewater Treatment Directive in particular stands out as an unprecedented threat for the sector. This session will explore how this can be addressed and how we can achieve closer coordination between industrial, healthcare and environment policymaking.

Moderator: Ines Windisch - Head of Corporate Affairs and Sustainability, Zentiva

Speakers

- **Dr. Nikolaos S. Thomaidis** - Professor of Analytical Chemistry at the National and Kapodistrian University of Athens
- **Christos Gallis** - Head of Eastern Europe, Stada
- **Christine Årdal** - Senior Researcher, Norwegian Institute of Public Health

32nd Annual CONFERENCE

DIVANI CARAVEL HOTEL, ATHENS

10 – 11 JUNE 2026
WITH WELCOME COCKTAIL ON 9 JUNE 2026

17.45 – 17.50



Closing address: Adrian van den Hoven - Director General, Medicines for Europe

18.30



Bus to conference dinner

THURSDAY 11 JUNE 2026

08.30 – 09.00



Start of the day welcome coffee

09.00 – 10.15



Session 4 – The off patent medicines industry - a strategic partner for health security

As a cornerstone of Europe's supply of essential medicines, the off-patent sector plays a vital role in safeguarding continuity of care, supporting civil protection efforts, and underpinning health security. Aligning health needs, civil protection, and crisis-preparedness can strengthen Europe's capacity to respond to health emergencies while ensuring access in normal times. This session will explore how sustainable markets for off-patent medicines are essential to Europe's preparedness and resilience objectives. It will examine how procurement and market reforms at EU and national level can balance affordability with supply security, incentivise resilience, and ensure responsiveness in emergencies.

Moderator: Adrian van den Hoven - Director General, Medicines for Europe

Speakers

- **Csaba Gali** - Deputy Head, DG HERA, European Commission
- **Gloria Ghéquierre** - Deputy Head of Cabinet, Cabinet of the Minister of Health Frank Vandenbroucke, Belgian Federal Government (inv)
- **Marc Crouton** - President Region Europe, Fresenius Kabi
- **David Willey** - Chief of the Medical Office, NATO Support & Procurement Agency (NSPA)
- **Christine Årdal** - Senior Researcher, Norwegian Institute of Public Health
- **Monica Dias** - Head of Supply and Availability of Medicines and Medical Devices, EMA (inv)

10.15 – 10.45



Networking coffee break

10.45 – 11.00



International Health Partners

11.00 – 12.15



Session 5 – The off patent medicines industry - a strategic partner for patient access

The off-patent medicines industry is a significant contributor to ensuring population health and delivering tangible benefits for patients across Europe. Generics and biosimilars enable health systems to treat more patients, earlier and more effectively, while value added medicines innovate on existing treatments, delivering better outcomes for patients and health systems. Patient access to these benefits, however, depend on the sustainability of the off-patent medicines market. Persistent downward pricing pressure and policies focused solely on cost-minimisation risk undermining competition, supply reliability, and future patient benefits. The discussion will therefore examine how demand-side policies and coherent pricing and reimbursement approaches can safeguard the industry's ability to continue delivering value for patients, now and in the years ahead.

Moderator: Katerina Patavou - Head of European Public Affairs and Social Impact Strategist, Panhellenic Union of Pharmaceutical Industries (PEF)

Speakers

- **Ms. Sonia García** - Advisory member, Spanish Ministry of Health
- **Ilaria Passarani** - Secretary General, PGEU
- **Christophe Delenta** - President Europe, Sandoz
- **Michal Nitka** - SVP, Head Generics Europe & Global Head OTC, Teva
- **Nikos Dedes** - Secretary General, Greek Patient (inv)

12.15 – 13.30



Networking buffet lunch

13.30 – 14.45



Session 6 – The off patent medicines industry - a strategic partner in uncertain times

Trade tensions, fragmentation, and growing geopolitical uncertainty are reshaping the global environment for the off-patent medicines industry. Navigating the intersection between politics and business becomes ever more important for companies to succeed in this new world. This session will focus on the role the Europe can play in alleviating some of these uncertainties and ensuring enabling conditions for its strategic industries, as well as how business leaders are adapting to manage uncertainty and make investment decisions in an increasingly volatile world, as well as on how emerging global partnerships and evolving trade opportunities could help reinforce Europe's competitiveness and supply resilience.

Moderator: Sergio Napolitano - General Counsel & Executive Director, Legal & International Affairs, Medicines for Europe

Panellists

- **Lucas Sigman** - CEO Insud Pharma and Chair, IGBA CEO Advisory Committee
- **James Pfitzer** - Viatrix (inv)
- **Marta Wosinska** - Brookings Institute (inv)



32nd Annual CONFERENCE

DIVANI CARAVEL HOTEL, ATHENS

10 – 11 JUNE 2026

WITH WELCOME COCKTAIL ON 9 JUNE 2026

- **Mariano Genovesi** - General Counsel and Intellectual Property Director, Argentinian Pharmaceutical Industry Chamber (CILFA) and IGBA Vice-Chair

14.45 – 15.00



Closure of the Conference

Co-hosted by



XPONIA
Παράγουμε Ελλάδα



ΠΑΝΕΛΛΗΝΙΑ
ΕΝΩΣΗ
ΦΑΡΜΑΚΟΒΙΟΜΗΧΑΝΙΑΣ

Platinum Sponsors



DEMO S.A.
PHARMACEUTICAL INDUSTRY

ELPEN

Gold Sponsors



**FRESENIUS
KABI**



Rontis
Driven by innovation

Silver Sponsors

Baxter



INSUD PHARMA



STADA

ZENTIVA

Conference Sponsor



genepharma

Media Partner

GaBi

For further information and to register for the Annual Medicines for Europe Conference, click [here](#).